Subject Matter Expert Consultant for Drug Metabolism Pharmacokinetics [DMPK]

The National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services' National Institutes of Health, is soliciting quotations for a Subject Matter Expert Consultant in Drug Metabolism Pharmacokinetics (DMPK) to support the NIH Blueprint Neurotherapeutics Network program. The contractor must provide an executive-level scientific consultant with a minimum of 15 years of experience in pharmacokinetics and drug metabolism, preferably with expertise in nervous system drug development. Key responsibilities include evaluating pharmacokinetic study protocols, developing strategic plans for drug discovery programs, assisting with regulatory documentation, and facilitating team discussions through video conferences, email communications, and occasional site visits. The evaluation will focus primarily on technical qualifications including professional experience in drug discovery and development, educational credentials, and collaborative team experience, with technical factors significantly more important than price and past performance. Quotations must include a capability letter, consultant resume, and completed pricing template, and are due by August 22, 2025, at 12:00 PM Eastern Time.

This opportunity is designated as a total small business set-aside under NAICS code 541990 with a size standard of $19 million, conducted using simplified acquisition procedures under FAR Parts 12 and 13. The contract is structured as a Labor Hour Purchase Order for a one-year base period with an estimated minimum of 20 annual hours and a not-to-exceed maximum of 800 optional hours. No incumbent contractors are identified in the solicitation documents. Performance will primarily occur at the contractor's location with occasional site visits required, while the contracting office is located in Bethesda, Maryland. The government reserves the right to make one award, multiple awards, or no awards based on the received quotations, and the acquisition is expected not to exceed the simplified acquisition threshold.